Physician profile
Maximo Santos
NPI 1841620424
$4,639.19
in general payments reported to CMS, 2019-2025
14 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 90% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $918 · 2022: $543 · 2023: $1,305 · 2024: $655 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,177.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,417.73 | 2021-2025 | Yeztugo |
| Viiv Healthcare Company | $1,610.83 | 2021-2025 | Cabenuva, Apretude, Dovato |
| Emd Serono, INC. | $119.30 | 2021-2025 | |
| Amarin Pharma, INC. | $92.55 | 2021 | |
| Theratechnologies INC. | $77.83 | 2023 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $54.87 | 2022-2023 | Symtuza |
| Hologic Sales and Service, LLC | $47.83 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $43.88 | 2024-2025 | |
| Napo Pharmaceuticals INC | $42.34 | 2021-2024 | Mytesi |
| Merck Sharp & Dohme LLC | $35.71 | 2022-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Axsome Therapeutics, INC. | $27.47 | 2023 | Auvelity |
| Abbvie INC. | $26.69 | 2022 | |
| Braeburn INC. | $22.34 | 2025 | Brixadi |
| Exact Sciences Corporation | $19.82 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maximo Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.